Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Ocugen, Inc (OCGN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Ocugen's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
2.230 -0.010    -0.45%
20/05 - Closed. Currency in USD ( Disclaimer )
After Hours
2.190
-0.040
-1.794%
19:59:32 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US67577C1053 
CUSIP:  67577C105
  • Volume: 5,234,273
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 2.045 - 2.330
Ocugen 2.230 -0.010 -0.45%

Ocugen, Inc Company Profile

 
Get an in-depth profile of Ocugen, Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology
SectorHealthcare
Employees

15

Equity Type

ORD

Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine is developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a novel biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Contact Information

Address 263 Great Valley Parkway Suite 160
Malvern, 19355
United States
Phone 484 328 4701
Fax -
Web www.ocugen.com

Top Executives

Name Age Since Title
Uday B. Kompella 54 2019 Co-founder & Independent Director
David S. Boyer - - Member of Retina Scientific Advisory Board
Manish Potti 34 2019 Independent Director
Kirsten M. Castillo 48 2020 Independent Director
Junge Zhang 54 2019 Independent Director
Ravi T. Achar - - Director
Geeta Lalwani - - Member of Retina Scientific Advisory Board
Ramesh Kumar 65 2019 Independent Director
Shankar Musunuri 57 2019 Co-Founder, Chairman & CEO
Prabhavathi B. Fernandes 72 2020 Independent Director
Carl D. Regillo - 2019 Member of Retina Scientific Advisory Board
Mark Pennesi - 2019 Member of Retina Scientific Advisory Board
Catherine J. Pachuk 64 2020 Vaccine Scientific Advisory Board Member
David Fajgenbaum - 2020 Vaccine Scientific Advisory Board Member
Susan Weiss - 2020 Vaccine Scientific Advisory Board Member
Satishchandran Chandrasekhar - 2020 Vaccine Scientific Advisory Board Member
Harvey Rubin - 2020 Vaccine Scientific Advisory Board Member
Bruce D. Forrest 59 2020 Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member
Marna Cupp Whittington 74 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

OCGN Comments

Write your thoughts about Ocugen, Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Paco Bv
Pacob Apr 25, 2022 12:04PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
April 25, 2022 7:33 AM EDT ~ Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Reply
2 1
Report
Paco Bv
Pacob Apr 18, 2022 9:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
April 18, 2022 7:11 AM EDT ~ Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
Reply
7 0
Report
Trader Trader
Trader Trader Apr 18, 2022 9:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
lol. Pacob, you must be losing money holding this to keep typing irrelevant information just to make yourself happy.
Reply
0 1
Report
Paco Bv
Pacob Apr 18, 2022 9:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
one thing is true, that news made me happy
Reply
1 0
Report
Trader Trader
Trader Trader Apr 18, 2022 9:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Pacob, covid is almost over in USA and Ocugen can only make money selling covaxin in USA. Furthermore, OCGN still has not submited an application to FDA, I believe. I am surprised stock price is still this high.
Reply
1 1
Report
Paco Bv
Pacob Apr 18, 2022 9:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
new variant landed in Europe, time to take a deep breath, to savor this brief moment of freedom, soon you will miss it deeply
Reply
1 2
Report
Trader Trader
Trader Trader Apr 18, 2022 9:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
lol You must live in a cave and believe all this. Do you live in USA?
Reply
1 0
Report
Paco Bv
Pacob Apr 01, 2022 9:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
April 1, 2022 7:37 AM EDT ~ Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Reply
3 0
Report
Kevin De Meester
Kevin De Meester Mar 17, 2022 10:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Finally some green
Reply
4 1
Report
Gandhi Mahatma
Gandhi Mahatma Mar 17, 2022 10:57AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Back above my average 😎
Reply
0 0
Report
NAGARAJAN MUNUSAMY
NAGARAJAN MUNUSAMY Mar 04, 2022 8:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Tesla...😎😎😎
Reply
2 5
Report
NAGARAJAN MUNUSAMY
NAGARAJAN MUNUSAMY Mar 04, 2022 8:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ocugen, $OCGN, request for pediatric use of COVID-19 vaccine rejected by FDA.
Reply
1 2
Report
Trader Trader
Trader Trader Mar 04, 2022 8:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
more like Yugo.
Reply
0 1
Report
Vlas Dacian
Vlas Dacian Mar 04, 2022 7:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1.5$
Reply
0 4
Report
NAGARAJAN MUNUSAMY
NAGARAJAN MUNUSAMY Mar 03, 2022 10:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
no revenue🤣🤣🤣
Reply
1 1
Report
Gandhi Mahatma
Gandhi Mahatma Mar 03, 2022 10:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
You are literally all over the place with this stock. Are u bullish or bearish? Make up your mind ffs
Reply
1 0
Report
Ole Rii
Ole Rii Mar 03, 2022 10:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ahahahahahaha
Reply
0 0
Report
Gábor Simon
Gábor Simon Mar 03, 2022 10:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What a recognition. Has it ever been at all?
Reply
1 0
Report
Paco Bv
Pacob Feb 24, 2022 2:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
COVAXIN is the safest for children, has a good balance between safety and efficacy, also more persistent than some of the best. Not enough for u? Here : 'when combining shots of vaccines with different technology, immunity is stronger'
Reply
1 0
Report
Trader Trader
Trader Trader Feb 24, 2022 2:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
blah blah blah. vaccine no one uses in USA and you keep going blah blah
Reply
0 2
Report
Trader Trader
Trader Trader Feb 24, 2022 2:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
children do NOT need to get vaccinated. science clearly shows that.
Reply
1 2
Report
Trader Trader
Trader Trader Feb 24, 2022 2:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
children do NOT need to get vaccinated
Reply
2 2
Report
Paco Bv
Pacob Feb 24, 2022 2:50PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
they r very contagious, children touch everything and they infect the whole family, they cause many job aussences, it goes against business productivity
Reply
2 1
Report
Nasset Abdulla
Nasset Abdulla Feb 23, 2022 4:58PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Earning in two days ? What do you guys think i bought will we see a bew high again 🕺🏾🙌🎉
Reply
0 0
Report
Trader Trader
Trader Trader Feb 23, 2022 4:58PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Nasset, OCGN has no revenue. What earning are you looking for?
Reply
2 0
Report
NAGARAJAN MUNUSAMY
NAGARAJAN MUNUSAMY Feb 23, 2022 4:58PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
👍👍👍👍
Reply
1 0
Report
NAGARAJAN MUNUSAMY
NAGARAJAN MUNUSAMY Feb 23, 2022 9:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
18% dropped.any info🤗
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email